National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 48546 [2015-19940]
Download as PDF
<![CDATA[
48546
Federal Register / Vol. 80, No. 156 / Thursday, August 13, 2015 / Notices
Publication
Kaur S, et al. Role of CD47 in triple
negative breast cancer. FASEB J. 2015
April;29(1 Supplement); Abstract 890.5.
[https://www.fasebj.org/content/29/1_
Supplement/890.5]
Intellectual Property: HHS Reference
No. E–263–2014/0—US Application No.
62/062,675 filed October 10, 2014.
tkelley on DSK3SPTVN1PROD with NOTICES
Related Technologies
• HHS Reference No. E–227–2006/
5—US Patent 8,236,313 issued August
7, 2012; US Patent 8,557,788 issued
October 15, 2013; US Patent 8,865,672
issued October 21, 2014.
• HHS Reference No. E–153–2008/
0—US Patent No. 8,951,527 issued
February 10, 2015.
• HHS Reference No. E–086–2012/
1—US Patent Application No. 61/
735,701 filed December 11, 2012.
• HHS Reference No. E–296–2011/
0—Application PCT/US2014/025989
filed March 13, 2014.
Licensing Contact: Jaime M. Greene;
301–435–5559; jaime.greene@
mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of
Pathology, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize methods to differentiate
cancer stem cells. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at hewesj@mail.nih.gov.
Prevention or Treatment of Viral
Infections by Inhibition of the Histone
Methyltransferases EZH1/2
Description of Technology: Herpes
simplex viral infections, including
herpes simplex virus type 1 (HSV–1)
and type 2 (HSV–2), are exceptionally
common worldwide. These viruses
establish lifelong persistent infections
with cycles of lytic reactivation to
produce recurrent diseases including
oral and genital lesions, herpetic
keratitis/blindness, congenitaldevelopmental syndromes, and viral
encephalitis. Infection with HSV–2
increases the rate of human
immunodeficiency virus (HIV)
transmission in coinfected individuals.
DNA replication inhibitors are typically
used to treat herpesvirus infections.
However, these compounds do not
completely suppress infection, viral
shedding, reactivation from latency, and
the inflammation that contributes to
diseases such as keratitis. An unmet
need continues to exist for methods of
preventing or treating herpesviral
infections. The application claims
methods of preventing or treating
VerDate Sep<11>2014
16:56 Aug 12, 2015
Jkt 235001
herpesviral infection of a host,
comprising administering to the host an
effective amount of an inhibitor of the
EZH1/2 histone methyltransferase
activities. The application is not limited
to herpes simplex virus but rather is
applicable to other viral infections as
well.
Potential Commercial Applications
• HSV therapeutics
• HSV vaccines
Competitive Advantages
• Low-cost production
• Ease of synthesis
Development Stage
• In vitro data available
• In vivo data available (animal)
Inventors: Thomas M. Kristie and
Jesse H. Arbuckle (NIAID)
Intellectual Property: HHS Reference
E–141–2015/0—US Provisional Patent
Application 62/155,704 filed 01 May
2015
Related Technologies
• HHS Reference E–275–2008/0—US
Patent Number 8,916,596 issued 23 Dec
2014; US Application No. 14/543,321
filed 17 Nov 2014; PCT Application No.
PCT/US2009/051557 filed 23 Jul 2009
• HHS Reference E–184–2010/0—US
Patent Number 8,871,789 issued 28 Oct
2014; PCT Application No. PCT/
US2011/044835 filed 21 Jul 2011
Licensing Contact: Peter Soukas; 301–
435–4646; ps193c@nih.gov
Dated: August 7, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–19912 Filed 8–12–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDDK.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
PO 00000
Frm 00071
Fmt 4703
Sfmt 9990
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
NATIONAL INSTITUTE OF DIABETES
AND DIGESTIVE AND KIDNEY
DISEASES, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors, NIDDK.
Date: September 10–11, 2015.
Open: September 10, 2015, 8:00 a.m. to
8:20 a.m.
Agenda: Introductions and Overview.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Closed: September 10, 2015, 8:20 a.m. to
5:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Closed: September 11, 2015, 8:00 a.m. to
4:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Contact Person: Michael W. Krause, Ph.D.,
Scientific Director, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Building 5,
Room B104, Bethesda, MD 20892–1818, (301)
402–4633, mwkrause@helix.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 10, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–19940 Filed 8–12–15; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 80, Number 156 (Thursday, August 13, 2015)]
[Notices]
[Page 48546]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-19940]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Board of Scientific Counselors, NIDDK.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the NATIONAL
INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES, including
consideration of personnel qualifications and performance, and the
competence of individual investigators, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NIDDK.
Date: September 10-11, 2015.
Open: September 10, 2015, 8:00 a.m. to 8:20 a.m.
Agenda: Introductions and Overview.
Place: National Institutes of Health, Building 5, Room 127, 5
Memorial Drive, Bethesda, MD 20892.
Closed: September 10, 2015, 8:20 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 5, Room 127, 5
Memorial Drive, Bethesda, MD 20892.
Closed: September 11, 2015, 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 5, Room 127, 5
Memorial Drive, Bethesda, MD 20892.
Contact Person: Michael W. Krause, Ph.D., Scientific Director,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Building 5, Room B104, Bethesda, MD
20892-1818, (301) 402-4633, mwkrause@helix.nih.gov.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: August 10, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-19940 Filed 8-12-15; 8:45 am]
BILLING CODE 4140-01-P
